SCHEMBL17130648

SCHEMBL17130648

Nc1cc(=O)[nH]c(SCC(=O)Nc2ccc(C(=O)O)cc2)n1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.77
ALDH1A1 P00352 5/20 0.76
HPGD P15428 2/20 0.76
KLK7 P49862 1/20 0.72
MAPT P10636 4/20 0.71
KMT2A Q03164 3/20 0.68
HTT P42858 1/20 0.68
POLB P06746 4/20 0.67
RAB9A P51151 3/20 0.67
RECQL P46063 3/20 0.67
MEN1 O00255 2/20 0.63
KDM4E B2RXH2 2/20 0.61
NPC1 O15118 1/20 0.61
TDP1 Q9NUW8 2/20 0.61
CYP3A4 P08684 1/20 0.61
CYP2C9 P11712 1/20 0.61
L3MBTL1 Q9Y468 2/20 0.59
LMNA P02545 1/20 0.59
USP2 O75604 1/20 0.58
ESR1 P03372 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20313771 0.89 SMN1; SMN2 (0.61) SMN1; SMN2ALDH1A1HPGDKLK7MAPT
SCHEMBL17130650 0.88 SMN1; SMN2 (0.80) SMN1; SMN2ALDH1A1HPGDKLK7MAPT
SCHEMBL17130736 0.88 MAPT (0.78) SMN1; SMN2ALDH1A1HPGDKLK7MAPT
SCHEMBL17130733 0.87 SMN1; SMN2 (0.79) SMN1; SMN2ALDH1A1KLK7MAPTKMT2A
SCHEMBL17130752 0.86 SMN1; SMN2 (0.74) SMN1; SMN2ALDH1A1HPGDKLK7MAPT
SCHEMBL17130651 0.85 MAPT (0.81) SMN1; SMN2ALDH1A1HPGDKLK7MAPT
SCHEMBL17130741 0.84 SMN1; SMN2 (0.59) SMN1; SMN2ALDH1A1HPGDKLK7MAPT
SCHEMBL11887745 0.84 POLB (0.78) SMN1; SMN2ALDH1A1KLK7MAPTKMT2A
SCHEMBL17130747 0.83 KLK7 (0.74) SMN1; SMN2ALDH1A1HPGDKLK7MAPT
SCHEMBL17130756 0.83 SMN1; SMN2 (0.72) SMN1; SMN2ALDH1A1KLK7MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180179166-A1 SMALL MOLECULE INHIBITORS OF GP120-MEDIATED HIV INFECTION AND METHODS OF USE VIROCARB INC (CA) 2018-06-28 US disclosed
US-20180179166-A1 SMALL MOLECULE INHIBITORS OF GP120-MEDIATED HIV INFECTION AND METHODS OF USE VIROCARB INC (CA) 2018-06-28 US disclosed
WO-2015143535-A1 SMALL MOLECULE INHIBITORS OF GP120-MEDIATED HIV INFECTION AND METHODS OF USE VIROCARB INC. (CA) 2015-10-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180179166-A1 SMALL MOLECULE INHIBITORS OF GP120-MEDIATED HIV INFECTION AND METHODS OF USE CD4, HAVCR2, CCR5 SMN1; SMN2 4801/4885ALDH1A1 2880/4885HPGD 359/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.